OvaRex

OvaRex is a monoclonal antibody that was developed for the treatment of ovarian cancer. It is also known as Oregovomab or MAb B43.13. The drug was developed by ViRexx Medical Corp, a company based in Edmonton, Alberta, Canada.

History

OvaRex was developed in the late 1990s and early 2000s. It was initially developed by ViRexx Medical Corp, a company that specializes in the development of new treatments for cancer and chronic viral infections. The drug was later acquired by Unither Pharmaceuticals, a subsidiary of United Therapeutics.

Mechanism of Action

OvaRex is a monoclonal antibody that targets the CA-125 antigen, a protein that is often overexpressed in ovarian cancer cells. By binding to this antigen, OvaRex is thought to stimulate the body's immune system to attack the cancer cells.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of OvaRex. These trials have shown that the drug is well-tolerated and can improve survival rates in women with ovarian cancer. However, further research is needed to confirm these findings and to determine the optimal dosing regimen for this drug.

Side Effects

Like all drugs, OvaRex can cause side effects. The most common side effects reported in clinical trials include fatigue, fever, and nausea. Less common side effects include allergic reactions, skin rash, and changes in blood pressure.

See Also

• Monoclonal antibodies
• Ovarian cancer
• CA-125
• Clinical trial

OvaRex Resources
Latest articles Most recent articles Ongoing trials	Wikipedia